Orion Energy Systems (OESX) Q1 2026 Earnings Call August 06, 2025 10:00 AM ET Speaker0Good day and thank you for standing by. Welcome to the Orion Energy Systems Fiscal twenty twenty six First Quarter Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. To wi ...

Evolus (EOLS) Q2 2025 Earnings Call August 05, 2025 04:30 PM ET Speaker0Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Second Quarter Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live. All participants are in a listen only mode. After the speakers' remarks, there will be a question and answer session.I would now like to turn the conference over to Narek Segarian, Vice President and Head of Global Investor Relations and Corporate Commun ...

Financial Data and Key Metrics Changes - Total revenues grew 16% in Q2 2025 and 15% year-over-year compared to the same periods in 2024, driven by strong global demand and new patient starts [13][19] - Non-GAAP diluted earnings per share increased to $1.44, reflecting a growth rate more than three times that of revenue growth [18] - Operating cash flow reached $185 million in Q2, a 55% increase compared to the same period in 2024 [18] Business Line Data and Key Metrics Changes - VOXZOGO revenue increased 20% year-over-year to $221 million, supported by global expansion and new patient starts [13][20] - Enzyme Therapies revenue rose 15% year-over-year to $555 million, with Palynziq and Vimizim contributing significantly to growth [15][26] - Rocadian revenue was $9 million in Q2, primarily from the U.S. and Italy [15] Market Data and Key Metrics Changes - The company expects second half VOXZOGO revenue to be higher than the first half, with full-year revenue guidance adjusted to between $900 million and $935 million [14][15] - The company anticipates continued strong growth in the second half of 2025, leading to an increase in full-year guidance for total revenues [11][19] Company Strategy and Development Direction - The company plans to advance BMN 333, a long-acting therapy for achondroplasia, to a registrational Phase 2/3 study in the first half of next year [9][28] - The acquisition of Inozyme broadens the enzyme therapies portfolio, with a focus on BMN 401 for ENPP1 deficiency [10][31] - The company aims to augment its portfolio with strategic business development transactions to diversify growth strategies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong growth and value creation for stakeholders through the remainder of 2025 and beyond [11][19] - The management highlighted the essential nature of their medicines and strong patient support programs as key factors in maintaining availability for patients [26] Other Important Information - The company expects to account for the Inozyme acquisition as an asset purchase, impacting financial results in 2025 [19] - The company is on track to submit applications for age extension for Palynziq to include adolescents in the U.S. and EU in the second half of this year [30] Q&A Session Summary Question: Clarification on BMN 333 and safety profile - Management confirmed that the agent referred to is Trans Con CNP and stated that no unexpected safety issues have been observed in the healthy volunteer study [36][38] Question: Thoughts on competitive landscape for achondroplasia - Management noted that while early data showed added growth with growth hormone, long-term benefits remain uncertain, and further data is needed to assess the impact of combinations [42][45] Question: Contributions to VOXZOGO guidance - Management explained that the adjustment in guidance is primarily due to shifting large orders and a better understanding of revenue trends as the year progresses [50][52] Question: Update on ITC proceedings - Management expects the initial determination from the ITC on June 8, 2026, with a completion date targeted for October 8, 2026 [56][58] Question: Details on BMN 333 trial design - Management refrained from providing specific details on powering but expressed confidence in the biological hypothesis being tested [58][60] Question: Update on citizen petition with the FDA - Management stated that the FDA is reviewing the citizen petition and no updates are expected until the PDUFA date of November 30 [88][90]

Financial Data and Key Metrics Changes - Worldwide revenue for Q2 2025 was $48.6 million, representing a growth of 21.7% year-over-year [30] - U.S. revenue was $46.4 million, reflecting a growth of 22.8% [31] - Adjusted EBITDA was positive at $1 million, compared to an adjusted EBITDA loss of $2.7 million in the prior year [34] - Net loss narrowed to $6.2 million or $0.14 per diluted share, compared to a net loss of $8.9 million or $0.22 per diluted share in the prior year [34] - Cash and marketable securities increased to $145.5 million, marking the first quarter of cash flow breakeven [35] Business Line Data and Key Metrics Changes - U.S. procedure volume increased by 25%, with double-digit growth across all modalities [10][32] - The physician base grew by 25%, reaching a record of 1,440 U.S. physicians performing procedures [22] - Average territory productivity reached $2.1 million, representing a 23% increase year-over-year [25] Market Data and Key Metrics Changes - International revenue was $2.2 million, impacted by delayed regulatory clearance for iFuse Torque in Europe [32] - The company expects iFuse Torque to boost revenue growth in Europe starting in 2026 [32] Company Strategy and Development Direction - The company aims to expand its platform of solutions targeting challenging procedures, improving surgical outcomes with lower failure rates [6][8] - Focus on innovation, physician engagement, commercial execution, and operational excellence as key priorities [12] - Plans to launch new products targeting outpatient settings and expand into new addressable markets [21][86] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand across the portfolio and the effectiveness of their strategy [44] - The company anticipates continued growth driven by strong physician engagement and product adoption [80] - Guidance for full-year revenue was updated to $195 million to $198 million, implying year-over-year growth of approximately 17% to 18% [36] Other Important Information - The company achieved cash flow breakeven ahead of schedule, indicating potential for consistent positive free cash flow [35] - Leadership changes were announced, with Tony Recoupero retiring and Nicholas Kerr promoted to Chief Commercial Officer [27][28] Q&A Session Summary Question: Guidance on top line growth and assumptions for the second half - Management highlighted strong first-half performance and confidence in continued demand, with a sequential decline expected in Q3 due to seasonality [40][46] Question: Gross margin guidance and pricing pressure - Management discussed maintaining gross margin guidance at 78.5% to 79%, embedding assumptions for ASP pressure while acknowledging potential for better-than-expected outcomes [51][56] Question: Growth of interventional doctors using products - Management noted strong growth from interventional doctors and the potential for further engagement with new product launches [60][62] Question: International market contribution and torque rollout in Europe - Management expressed optimism about the torque product's impact in Europe, with expectations for growth in 2026 [95] Question: Capital deployment priorities - Management indicated a focus on continued investment in R&D and commercial initiatives while maintaining a strong cash position [98]

Key Takeaways NVDA, AVGO and NOW are highlighted for their strong net income ratios and profitability metrics. Each firm showed higher-than-industry sales and income growth over the trailing 12-month period.All three stocks met strict screening criteria, narrowing 7,685 stocks down to a final group of 11.Investors should look for companies that generate strong returns after accounting for all operating and non-operating expenses. Therefore, it’s wise to invest in a profitable company rather than one that is ...

Core Viewpoint - Fastly (FSLY) is expected to report its second-quarter 2025 results on August 6, with anticipated revenue growth and a narrower non-GAAP loss compared to the previous year [1][2][9]. Revenue Expectations - FSLY expects revenues in the range of $143 million to $147 million, representing a 10% year-over-year increase at the midpoint [1][9]. - The Zacks Consensus Estimate for revenues is $145.1 million, indicating a 9.6% increase from the same quarter last year [1]. Loss Forecast - The company anticipates a non-GAAP loss between 4 and 8 cents per share, with the consensus mark for loss at 5 cents per share, which is an improvement from the 7 cents loss reported in the previous year [2][9]. Key Growth Drivers - Fastly's content delivery and edge computing platform is expected to benefit from go-to-market transformation efforts and packaging improvements, aiding in deal acquisition and steady revenue growth [3]. - Enterprise demand for advanced digital experiences and security solutions is likely to support top-line growth, with the Security segment benefiting from ongoing portfolio enhancements [4]. Market Dynamics - Adoption of edge computing solutions, particularly for dynamic content and AI-driven workloads, has been a significant catalyst for growth [4]. - Traditional content delivery remains the primary revenue driver, while security and compute offerings are helping to diversify the revenue mix [4]. Challenges - Competitive industry pricing may constrain gross margin expansion, and profitability is closely tied to operating discipline [6]. - Macroeconomic uncertainty and regulatory factors related to specific customer relationships are expected to negatively impact second-quarter results [6]. Earnings Outlook - According to the Zacks model, FSLY has an Earnings ESP of -53.13% and a Zacks Rank of 3, indicating lower odds of an earnings beat [7].

If history is any indication, shareholders will benefit sooner rather than later.Lyft (LYFT -3.13%) is a ride-hailing platform that has had a complete margin makeover in recent years. And it feels like nobody even noticed.CEO David Risher took over in April 2023, vowing to prioritize better cash flow. For perspective, the company had a net loss of $1.6 billion in 2022 and more than $350 million in negative free cash flow. Those numbers looked terrible.However, Lyft has generated more than $900 million in fr ...

Core Viewpoint - Peloton Interactive Inc. is facing significant challenges, including tariffs and sales pressure, as it prepares to report its fourth-quarter and full-year fiscal 2025 earnings, with analysts maintaining a cautious outlook on the company's growth prospects [1][2][3]. Financial Performance - Peloton is expected to report a 9% year-over-year decline in quarterly sales to $586 million, which is at the high end of company guidance and slightly above the FactSet consensus of $581 million [4]. - The company anticipates a near-term impact of approximately $5 million in free cash flow pressure for the fourth quarter due to evolving trade conditions [2]. - Adjusted EBITDA is projected to be $85 million, near the top of the company's implied range of $66 million to $86 million, while gross margin is expected to be 51.4%, trailing the 52.3% consensus [5]. Subscriber and Revenue Trends - Connected fitness subscribers are forecasted to decline by 5.8% year-over-year and 3% sequentially to 2.81 million [5]. - Hardware sales are estimated to drop by 17%, and subscription revenue is expected to decrease by 5% [4]. Strategic Initiatives - The company has implemented strategic changes, including leadership adjustments under CEO Peter Stern, promotional activities during Amazon Prime Day, and potential modifications to the $44 all-access membership fee [3]. - The launch of the Peloton Repowered marketplace is also part of the company's efforts to innovate and retain customers [3]. Analyst Ratings and Market Performance - Telsey Advisory Group analyst Dana Telsey has reiterated a Market Perform rating on Peloton with a price forecast of $8, applying a ~1.5x EV/Sales multiple to the FY26 sales forecast of $2.47 billion [1][4]. - Peloton shares were trading lower by 7.91% to $6.58 at the time of publication [5].

Financial Data and Key Metrics Changes - The company reported its twelfth consecutive quarter of profitability, achieving a total revenue of $263.6 million, which is 3.6% higher than the previous year despite a 0.5% decrease in total block hours [13][14] - The GAAP pretax margin was 3.2%, and the adjusted pretax margin was 3.9%, marking the third consecutive quarter of total revenue growth year-over-year and improvement in pretax margin [13] - The company expects to generate approximately $1.5 billion in revenue, $300 million in EBITDA, and $2.5 in EPS by 2027 [10][11] Business Line Data and Key Metrics Changes - Revenue from the cargo segment grew 36.8% year-over-year to $34.8 million, marking the highest quarterly cargo revenue in the company's history [16] - Scheduled service revenue, which includes both scheduled and charter businesses, decreased by 0.8% year-over-year due to a significant reduction in scheduled service operations, with scheduled service ASMs declining by 6.2% [14][15] - Charter revenue increased by 6.4% to $54.3 million, supported by a 7.9% increase in charter block hours [15][16] Market Data and Key Metrics Changes - The company anticipates third-quarter total revenue to be between $250 million and $260 million, with block hours expected to increase by 5% to 8% [21] - The company noted that fuel prices decreased by 15% compared to the same period in 2024, impacting fuel reconciliation proceeds [16] Company Strategy and Development Direction - The company is focusing on growth in its cargo business, expecting to have all eight cargo additions in service by the end of the third quarter, which will double cargo revenue once fully utilized [6][14] - The strategy includes maintaining a diversified revenue stream and being nimble in capacity allocation to maximize profitability [34][36] - The company plans to continue building its balance sheet and is open to organic growth opportunities arising from industry disruptions [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver industry-leading profitability throughout all cycles, despite current challenges in scheduled service due to rapid cargo growth [5][6] - The management highlighted that the peak summer months could absorb more capacity than was delivered, with expectations of margin expansion as scheduled service is rebuilt [9][10] - Management noted that the current demand for their product remains strong, with bookings for the winter peak period looking promising [55][101] Other Important Information - The company expects to pay down an additional $44 million in debt by the end of the year, with total debt and lease obligations at $562 million at the end of Q2 [20][21] - The company has a share repurchase authorization of $25 million from its Board of Directors [21] Q&A Session Summary Question: Can you discuss the path to $2.50 EPS and industry conditions? - Management indicated that long-term revenue forecasts include a general inflation tailwind of about 3% and are based on stable unit revenue performance and predictable costs [24][25] Question: How is the peak season shaping up with Amazon? - Management noted delays in asset utilization due to aircraft preparation, but they expect to reach operational capacity soon [26][27] Question: What is the strategy regarding industry capacity and competition? - The company aims to execute well and look for organic growth opportunities while maintaining a strong balance sheet [34][36] Question: Can you provide insights on charter business modeling? - Management explained that charter business consists of long-term commitments and ad hoc opportunities, with expectations for stable margins [88][89] Question: How does the company view capital allocation? - The company plans to balance between shareholder returns and growth opportunities, focusing on free cash flow generation [66][68] Question: What are the expectations for the upcoming quarters? - Management expects Q4 to be strong due to peak holiday travel, with a gradual recovery in margins anticipated [74][75]

The Bitcoin Company ‘Strategy’ is Officially the Top 10th Most Profitable Public Company in America ...